DelveInsight’s “Androgenetic Alopecia – Market Insight, Epidemiology, And Market Forecast – 2034″ report offers an in-depth understanding of the Androgenetic Alopecia, historical and forecasted epidemiology as well as the Androgenetic Alopecia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Some of the key facts of the Androgenetic Alopecia Market Report:
• According to DelveInsight, the market for Androgenetic Alopecia in the 7MM was valued at approximately USD 6 million in 2023, with the US accounting for around USD 3 million.
• The total prevalent cases of Androgenetic Alopecia in the 7MM were around 195 million in 2023, with the US contributing to nearly 83 million cases. These numbers are projected to increase by 2034 due to factors like sedentary lifestyles leading to hormonal changes.
• In the US, the diagnosed prevalent cases of male Androgenetic Alopecia in 2023 were approximately 23 million, significantly higher than the 20 million diagnosed female cases, indicating a higher male prevalence.
• In April 2024, a randomized trial in Brazil showed that low-dose oral minoxidil (Rogaine) was well-tolerated and had similar efficacy to topical minoxidil, offering an alternative treatment for male Androgenetic Alopecia patients intolerant to topical treatments.
• In January 2024, Hope Medicine began recruiting participants for a Phase II trial assessing its monoclonal antibody, HMI-115, for Androgenetic Alopecia, after promising Phase Ib trial results in Australia.
• Emerging drugs in development for Androgenetic Alopecia include KX-826 (pyrilutamide), BREEZULA (clascoterone solution), Clascoterone, and others.
• Key companies involved in the Androgenetic Alopecia market include Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics, Kintor Pharmaceutical, Dong-A ST Co., Ltd., Cassiopea, Follica, Applied Biology, Inc., AndroScience Corporation, AnnJi Pharmaceutical, Carmell Therapeutics, Cosmo Pharmaceuticals, Merz Aesthetics, and others.
• The growing incidence of Androgenetic Alopecia, combined with the introduction of novel treatments and ongoing research, continues to drive the market’s expansion.
To Know in detail about the Androgenetic Alopecia market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Androgenetic Alopecia Market Forecast
Androgenetic Alopecia Overview
Androgenetic alopecia, commonly referred to as male or female pattern baldness, is a widespread form of hair loss marked by a gradual decline in hair density and thickness, following a distinct pattern. This condition affects both men and women, though its manifestation and progression vary between sexes. In men, it often starts with a receding hairline and thinning at the crown, which can advance to partial or complete baldness. Women, on the other hand, typically experience diffuse thinning over the crown while retaining their frontal hairline.
Androgenetic alopecia is primarily influenced by genetic and hormonal factors, particularly sensitivity to dihydrotestosterone (DHT), a testosterone derivative. DHT can shrink hair follicles, shorten the hair growth cycle, and ultimately lead to hair miniaturization and loss. While the condition is not medically serious, it can significantly impact psychological well-being, self-esteem, and overall quality of life.
Get a Free sample for the Androgenetic Alopecia Market Report: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
Androgenetic Alopecia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Androgenetic Alopecia Epidemiology Segmentation:
The androgenetic alopecia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total prevalence of androgenetic alopecia
• Total prevalence of androgenetic alopecia in males
• Total prevalence of androgenetic alopecia in females
• Total diagnosed prevalence of androgenetic alopecia in males
• Total diagnosed prevalence of androgenetic alopecia in females
Download the report to understand which factors are driving Androgenetic Alopecia epidemiology trends @ Androgenetic Alopecia Epidemiology Forecast
Androgenetic Alopecia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Androgenetic Alopecia market or expected to be launched during the study period. The analysis covers the Androgenetic Alopecia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Androgenetic Alopecia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Androgenetic Alopecia Market Strengths
• Advancements in therapeutic options, including FDA-approved drugs like finasteride and minoxidil, along with emerging regenerative therapies (e.g., platelet-rich plasma, stem cell therapy), are expanding treatment possibilities.
• Androgenetic alopecia is a widespread condition, affecting millions globally. Increasing awareness and demand for aesthetic and hair restoration solutions are driving market growth.
Androgenetic Alopecia Market Weaknesses
• Current pharmacological treatments often require continuous use to maintain results, with discontinuation leading to hair loss recurrence, limiting patient adherence.
• Advanced therapies such as hair transplants and regenerative medicine are expensive, making them inaccessible to a significant portion of the affected population, particularly in developing regions.
Scope of the Androgenetic Alopecia Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Androgenetic Alopecia Therapies: KX-826 (pyrilutamide), BREEZULA (clascoterone solution), Clascoterone, and others.
• Key Androgenetic Alopecia Companies: Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics, Kintor Pharmaceutical, Dong-A ST Co., Ltd., Cassiopea, Follica, Applied Biology, Inc., AndroScience Corporation, AnnJi Pharmaceutical, Carmell Therapeutics, Cosmo Pharmaceuticals, Merz Aesthetics, and others.
• Androgenetic Alopecia Therapeutic Assessment: Androgenetic Alopecia currently marketed and Androgenetic Alopecia emerging therapies
• Androgenetic Alopecia Market Dynamics: Androgenetic Alopecia market drivers and Androgenetic Alopecia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Androgenetic Alopecia Unmet Needs, KOL’s views, Analyst’s views, Androgenetic Alopecia Market Access and Reimbursement
To learn more about the key players and advancements in the Androgenetic Alopecia Treatment Landscape, visit the Androgenetic Alopecia Market Analysis Report
Table of Contents
1. Androgenetic Alopecia Market Report Introduction
2. Executive Summary for Androgenetic Alopecia
3. SWOT analysis of Androgenetic Alopecia
4. Androgenetic Alopecia Patient Share (%) Overview at a Glance
5. Androgenetic Alopecia Market Overview at a Glance
6. Androgenetic Alopecia Disease Background and Overview
7. Androgenetic Alopecia Epidemiology and Patient Population
8. Country-Specific Patient Population of Androgenetic Alopecia
9. Androgenetic Alopecia Current Treatment and Medical Practices
10. Androgenetic Alopecia Unmet Needs
11. Androgenetic Alopecia Emerging Therapies
12. Androgenetic Alopecia Market Outlook
13. Country-Wise Androgenetic Alopecia Market Analysis (2020–2034)
14. Androgenetic Alopecia Market Access and Reimbursement of Therapies
15. Androgenetic Alopecia Market Drivers
16. Androgenetic Alopecia Market Barriers
17. Androgenetic Alopecia Appendix
18. Androgenetic Alopecia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Jatin VimalEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
